1. Home
  2. SPE vs CRBU Comparison

SPE vs CRBU Comparison

Compare SPE & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Special Opportunities Fund Inc

SPE

Special Opportunities Fund Inc

HOLD

Current Price

$13.54

Market Cap

141.1M

Sector

Finance

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.82

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPE
CRBU
Founded
1993
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.1M
166.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SPE
CRBU
Price
$13.54
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
33.7K
2.4M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
8.55%
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.14
$1.38
52 Week High
$15.99
$3.53

Technical Indicators

Market Signals
Indicator
SPE
CRBU
Relative Strength Index (RSI) 43.91 50.23
Support Level $13.51 $1.70
Resistance Level $14.18 $2.02
Average True Range (ATR) 0.19 0.12
MACD 0.02 0.02
Stochastic Oscillator 47.47 70.83

Price Performance

Historical Comparison
SPE
CRBU

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: